Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717922 | 0.70 | MEN1 (0.35) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL30858393 | 0.67 | — | — | |
| SCHEMBL28072669 | 0.67 | MEN1 (0.35) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL37950 | 0.67 | MEN1 (0.35) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL317892 | 0.67 | MAPT (0.40) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL7398024 | 0.67 | MAPT (0.39) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL21316061 | 0.65 | MAPT (0.41) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL640436 | 0.65 | APAF1 (0.33) | MEN1NPC1POLBMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL4647777 | 0.65 | APAF1 (0.33) | MEN1NPC1POLBMAPTRAB9A | |
| SCHEMBL21359837 | 0.65 | MAPT (0.38) | MEN1NPC1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026944-A | Preparation method and application of dialkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-122056845-A | Esomeprazole enteric capsule, and preparation method and application thereof | 通化万通药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) | 2026-02-05 | — | — | US | disclosed |
| CN-116807990-B | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118026944-A | Preparation method and application of dialkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118026944-A | Preparation method and application of dialkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118026944-A | Preparation method and application of dialkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118026939-A | Preparation method and application of fluorine-containing alkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117142437-A | Preparation method of sulfuryl fluoride | 内蒙古图微新材料科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116807990-A | Esomeprazole magnesium enteric capsule and preparation method thereof | 桂林华信制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | PIK3R1, PIK3R4, PIK3R2 | G6PD 3381/4885MEN1 4252/4885NPC1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.